Nevirapine-induced side effects in pregnant women - Experience of a Brazilian University Hospital

Brazilian Journal of Infectious Diseases

Volumn 11, Issue 6, 2007, Pages 544-548

  Kondo, William ^a,b   Carraro, Elaine Aparecida ^a   Prandel, Elaine ^a   Dias, Josiane Mourão ^a   Perini, Juliane ^a   de Macedo, Rodolfo Lara ^a   Cornelsen, Taynah Cristina ^a   Sbalquiero, Renato ^a   Sasaki, Maria das Graças ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b NONE   (Brazil)

Author keywords

Hepatotoxicity; HIV 1; Nevirapine; Pregnancy; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAZIL; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; LIVER FUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MATERNAL TREATMENT; PREGNANT WOMAN; PRURITUS; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN DISEASE; UNIVERSITY HOSPITAL; VIRUS LOAD;

EID: 41149171654     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702007000600004     Document Type: Article

References (34)

1. Hitti J., Frenkel L.M., Stek A.M., et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 2004;36:772-6.
2. Lyons F., Hopkins S., Kelleher B., et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006;7:255-60.
3. Joy S., Poi M., Hughes L., et al. Third-trimester maternal toxicity with nevirapine use in pregnancy. Obstet Gynecol 2005;106:1032-8.
4. Joao E.C., Calvet G.A., Menezes J.A., et al. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol 2006; 194:199-202.
5. Ministério da Saúde. Recomendações para Profilaxia da Transmissão Vertical do HIV e Terapia Anti-Retroviral em Gestantes. Brasilia, 2006.
6. Mirochnick M., Siminski S., Fenton T., et al. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J 2001;20:803-5.
7. Guay L.A., Musoke P, Fleming T., et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802.
8. Marseille E., Kahn J.G., Mmiro F., et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet 1999; 354:803-9.
9. de Maat M.M., ter Heine R., van Gorp E.C., et al. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS 2003; 17:2209-14.
10. Martinez E., Blanco J.L., Arnaiz J.A., et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-8.
11. de Maat M.M., ter Heine R., Mulder J.W., et al. Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol 2003; 59:457-62.
12. Ena J., Amador C., Benito C., Fenoll V., Pasquau F. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS 2003;14:776-81.
13. Martin A.M., Nolan D., James I., et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1 *0101 and abrogated by low CD4 T-cell counts. AIDS 2005;19:97-9.
14. Dieterich D.T., Robinson P.A., Love J., Stern J.O. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004;38:S80-9.
15. Bersoff-Matcha S.J., Miller W.C., Aberg J.A., et al. Sex differences in nevirapine rash. Clin Infect Dis 2001;32:124-9.
16. Fagot J.P., Mockenhaupt M., Bouwes-Bavinck J.N., et al. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001;15:1843-8.
17. Gonzalez de Requena D., Nunez M., Jimenez-Nacher I., Soriano V. Liver toxicity caused by nevirapme. AIDS 2002;16:290-1.
18. Martin-Carbonero L., Nunez M., Gonzalez-Lahoz J., Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials 2003;4:115-20.
19. Ministério da Saúde. Protocolo para a prevenção de transmissão vertical de HIV e sífilis. Brasília, 2006.
20. AIDS Clinical Trial Group. Table of grading severity of adverse experiences. Rockville (MD): Division of AIDS, National Institute of Allergy and Infectious Diseases, 1996.
21. Guidelines for the management of hepatic events with Viramune. Available: www.viramune.com. 2006.
22. Stem J.O., Robinson P.A., Love J., et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003;34:S21-33.
23. Nunez M., Lana R., Mendoza J.L., et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:426-31.
24. Boehringer-Ingelheim Pharmaceuticals Inc. Viramune drug label. Revised September 4, 2003.
25. Centers for Disease Control and Prevention (CDC). Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR Moth Mortal Wkly Rep 2001; 49:1153-6.
26. Zhou J., Phanupak P., Kiertiburanakul S., et al. Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database. J Acquir Immune Defic Syndr 2006;43:501-3.
27. Wooltorton E. HIV drug nevirapine (Viramune): risk of severe hepatotoxicity. CMAJ 2004;170:1091.
28. Edwards S.G., Larbalestier N., Hay P., et al. Experience of nevirapine use in a London cohort of HIV-infected pregnant women. HIV Med 2001;2:89-91.
29. Jamisse L., Balkus J., Hitti J., et al. Antiretroviral-Associated Toxicity Among HIV-1-Seropositive Pregnant Women in Mozambique Receiving Nevirapine-Based Regimens. J Acquir Immune Defic Syndr 2007; 44:371-6.
30. Lyons F., Hopkins S., McGeary A., et al. Nevirapine tolerability in HIV infected women in pregnancy - A word of caution. 2nd IAS conference on HIV Pathogenesis and Treatment. Paris, France. July 13-16, 2003 [abstract LB27].
31. Langlet, P., Guillaume M.P., Devriendt J., et al. Fatal liver failure associated with nevirapine in a pregnant HIV patient: the first reported case Gastroenterol 2000;118: Abstract 6623.
32. Kramer F., Stek A., Du W.B., Kovacs A. Nevirapine tolerability in HIV-infected women in pregnancy. Eleventh Conference on Retrovirus and Opportunistic Infections [abstract 923]; February 2004; San Francisco, California.
33. Natarajan U., Pym A., McDonald C., et al. Safety of nevirapine in pregnancy. HIV Med 2007;8:64-9.
34. Marazzi M.C., Germano P., Liotta G., et al. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med 2006;7:338-44.